Abstract
In their letter, David Bomze and colleagues note that the restricted mean survival time provides an alternative approach to quantify treatment effect, and they estimate that 21% of patients included in KEYNOTE-177 had inferior overall survival with first-line pembrolizumab compared with first-line chemotherapy. We believe that these data highlight the need to investigate the molecular underpinnings of PD-1 resistance, and how best to overcome this resistance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
